US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Birth Control

1,303.57

-20.7150-1.56%

Number of Gainers:1

Number of Losers:4

Number of Flat:1

PE:- -

High:1,347.28

Open:1,330.97

Low:1,289.98

Close:1,324.29

Loading ...

Generation Bio Elects Directors and Approves Key Proposals

Generation Bio Co. Conducted Its Annual Stockholders Meeting

MannKind Corporation Unveils Presentation Highlighting Afrezza Growth, Strong Financials, and Pipeline Advancements

DarÉ Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market DarÉ’S Dare to Play Sildenafil Cream

THOMSON REUTERS

Teva Pharmaceutical Industries Raises Pool Tender Offer, Reports Early Tender Results

MT Newswires Live

Femasys Announces Public Offering and Private Placement

Femasys Inc. Announces Underwritten Offering of 3.6 Million Shares and Concurrent Private Placement of Over 1.6 Million Shares

Teva announces results from a study of treatment patterns of tardive dyskinesia

Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts

New Data From Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

THOMSON REUTERS

Femasys prices 3.6M shares at 85c in underwritten public offering

BRIEF-Femasys Announces Pricing Of Underwritten Public Offering And Concurrent Private Placement With Gross Proceeds Of $4.5 Million

Femasys Inc - Prices Public Offering of 3.6 Mln Shares at $0.85/Share

THOMSON REUTERS

Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement With Gross Proceeds of $4.5 Million

THOMSON REUTERS

Teva Pharmaceutical (TEVA) Receives a Buy from UBS

BUZZ-Australia's Lynas Rare Earths gains on signing rare earths deal with Malaysian co

Femasys Inc. Announces Public Offering of Common Stock and Concurrent Private Placement

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

THOMSON REUTERS

Teva reaffirms ‘Pivot to Growth’ strategy with launch of acceleration phase

Teva Reaffirms “Pivot to Growth” Strategy Progress With Launch of Acceleration Phase at 2025 Innovation and Strategy Day

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":1303.5731,"timestamp":1749153599999,"preClose":1324.2881,"halted":0,"volume":14827977,"delay":0,"changeRate":-0.015642,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-20.714966,"latestTime":"06-05 16:00:00 EDT","open":1330.9722,"high":1347.2792,"low":1289.9761,"amount":196823410.667427,"amplitude":0.043271,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749196800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.374435,"peRate":-15.303976,"turnoverRate":0.009003,"increases":1,"decrements":4,"flats":1,"marketCap":21255512016,"floatMarketCap":21111404452},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":1347.2792,"amplitude":0.043271,"preClose":1324.2881,"low":1289.9761,"pbRate":"3.374435","latestPrice":1303.5731,"volume":14827977,"delay":0,"open":1330.9722,"prevYearClose":1682.2216,"prevWeekClose":1265.8181,"prevMonthClose":1265.8181,"prevQuarterClose":1184.288,"fiveDayClose":1317.5505,"twentyDayClose":1336.9244,"sixtyDayClose":1240.3549,"secType":"PLATE","market":"US","turnoverRate":0.009003,"peRate":-15.303976,"marketCap":21255512016,"floatMarketCap":21111404452,"timestamp":1749153599999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":1,"down":4,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541960006","title":"Generation Bio Elects Directors and Approves Key Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2541960006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541960006?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:38","pubTimestamp":1749155887,"startTime":"0","endTime":"0","summary":"Generation Bio ( ($GBIO) ) has shared an announcement. On June 4, 2025, Generation Bio Co. conducted its annual meeting of stockholders, where key ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/generation-bio-elects-directors-and-approves-key-proposals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/generation-bio-elects-directors-and-approves-key-proposals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4584","GBIO"],"gpt_icon":0},{"id":"2541005384","title":"Generation Bio Co. Conducted Its Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541005384","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541005384?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:07","pubTimestamp":1749154039,"startTime":"0","endTime":"0","summary":"Generation Bio Co. held its annual meeting of stockholders on June 4, 2025. The stockholders elected Ron Cooper, Anthony Quinn, M.B. Ch.B., Ph.D., and Jason Rhodes as Class II directors to the board of directors. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to the company's restated certificate of incorporation to effect a reverse stock split of issued shares of common stock was also adopted and approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generation Bio Co. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL58m1dG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GBIO","BK4584"],"gpt_icon":0},{"id":"2541409008","title":"MannKind Corporation Unveils Presentation Highlighting Afrezza Growth, Strong Financials, and Pipeline Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2541409008","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541409008?lang=en_us&edition=fundamental","pubTime":"2025-06-06 02:57","pubTimestamp":1749149872,"startTime":"0","endTime":"0","summary":"MannKind Corporation recently held a presentation at the Jefferies Global Healthcare Conference, highlighting key aspects of its business performance and future plans. The company reported strong financial health with cash, cash equivalents, and investments totaling $198 million. MannKind's product, Afrezza, demonstrated a 20% growth in new prescriptions compared to the first quarter of 2024, with expectations for a label update by the fourth quarter of 2025. Additionally, the company plans to submit a supplemental Biologics License Application for pediatric indication expansion by mid-2025. The Tyvaso DPI collaboration contributed $30 million in royalty revenue and $29 million in manufacturing-related revenues during the first quarter. MannKind is also making progress in its pipeline, with the Clofazimine Inhalation Suspension on track to meet its interim enrollment target by the end of 2025, and plans to advance the Nintedanib DPI into the next phase of global development in the seco","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL5SkMqz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","MNKD","BK4139"],"gpt_icon":0},{"id":"2540063470","title":"DarÉ Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market DarÉ’S Dare to Play Sildenafil Cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2540063470","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540063470?lang=en_us&edition=fundamental","pubTime":"2025-06-04 20:00","pubTimestamp":1749038402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nTUAC3TF0Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DARE","BK4584"],"gpt_icon":0},{"id":"2540728067","title":"Teva Pharmaceutical Industries Raises Pool Tender Offer, Reports Early Tender Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2540728067","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540728067?lang=en_us&edition=fundamental","pubTime":"2025-06-03 21:27","pubTimestamp":1748957271,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  said Tuesday that it has exercised its right to further raise the pool tender cap for its pool 3 notes to a total purchase price of $400 million from $350 million previously.The pool 3 notes consist of US dollar-denominated 7.875% sustainability-linked senior notes due 2029, Euro-denominated 7.375% sustainability-linked senior notes due 2029, and US dollar-denominated 8.125% sustainability-linked senior notes due 2031, the company added.Teva said the pool tender caps for the pool 1 notes, which consist of US dollar-denominated 3.150% senior notes due 2026, and the pool 2 notes, which consist of US dollar-denominated 4.750% sustainability-linked senior notes due 2027 and Euro-denominated 3.750% sustainability-linked senior notes due 2027, remain unchanged.The combined total purchase price of the notes is increased to $2.30 billion from $2.25 billion, Teva said.A total of $2.60 billion of the pool 1 notes have been tendered, while a total of $1.39 billion ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4596","BK4566","POOL","IE00B64QTZ34.USD","BK4559","BK4159","BK4588","BK4007","BK4567","BK4557","TEVA","BK4584","BK4585"],"gpt_icon":0},{"id":"2540450760","title":"Femasys Announces Public Offering and Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2540450760","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540450760?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:51","pubTimestamp":1748865085,"startTime":"0","endTime":"0","summary":"Femasys ( ($FEMY) ) has issued an update. On May 29, 2025, Femasys Inc. entered into an underwriting agreement with JonesTrading Institutional Serv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/femasys-announces-public-offering-and-private-placement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/femasys-announces-public-offering-and-private-placement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FEMY","BK4082","BK4539","BK4584"],"gpt_icon":0},{"id":"2540767713","title":"Femasys Inc. Announces Underwritten Offering of 3.6 Million Shares and Concurrent Private Placement of Over 1.6 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2540767713","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540767713?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:30","pubTimestamp":1748863808,"startTime":"0","endTime":"0","summary":"Femasys Inc. Announces Underwritten Offering of 3.6 Million Shares and Concurrent Private Placement of Over 1.6 Million Shares. On May 29, 2025, Femasys Inc. entered into an underwriting agreement with JonesTrading Institutional Services LLC for a public offering of 3,600,000 shares at $0.85 per share, with an option for an additional 540,000 shares. Concurrently, Femasys also engaged in a private placement with certain existing institutional stockholders and its directors and officers, selling 1,588,235 shares at $0.85 each to the institutional investors and 98,040 shares at $1.02 each to the directors and officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news br","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLb49JJd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4584","FEMY","BK4082"],"gpt_icon":0},{"id":"2540730984","title":"Teva announces results from a study of treatment patterns of tardive dyskinesia","url":"https://stock-news.laohu8.com/highlight/detail?id=2540730984","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540730984?lang=en_us&edition=fundamental","pubTime":"2025-06-02 04:20","pubTimestamp":1748809205,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced results from a study of treatment patterns among patient...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-results-from-a-study-of-treatment-patterns-of-tardive-dyskinesia-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-results-from-a-study-of-treatment-patterns-of-tardive-dyskinesia-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4585","BK4596","BK4584","BK4557","BK4588","TEVA","BK4559","BK4566"],"gpt_icon":0},{"id":"2539783446","title":"Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2539783446","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539783446?lang=en_us&edition=fundamental","pubTime":"2025-05-31 17:01","pubTimestamp":1748682071,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($KYTX) ), ( ($RCKT) ), ( ($TEVA) ), ( ($FICO) ) and ( ($OKLO) ). Here is a breakdown of their recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/kyverna-rocket-teva-fair-isaac-oklo-trending-by-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/kyverna-rocket-teva-fair-isaac-oklo-trending-by-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4608","LU0289739343.SGD","LU2360106780.USD","BK4559","LU0069063385.USD","FICO","BK4588","TEVA","LU2087625088.SGD","LU0056508442.USD","BK4023","LU0472753341.HKD","LU0353189763.USD","IE00B64QTZ34.USD","BK4566","LU1852331112.SGD","IE00BLDYK493.USD","BK4585","LU0057025933.USD","LU0511384066.AUD","LU2250418816.HKD","BK4596","BK4557","BK4584","LU0353189680.USD","BK4007","LU0289961442.SGD"],"gpt_icon":0},{"id":"2539209900","title":"New Data From Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2539209900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539209900?lang=en_us&edition=fundamental","pubTime":"2025-05-31 09:05","pubTimestamp":1748653500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nTUA5FN2HW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4585","BK4596","BK4584","BK4557","BK4588","TEVA","BK4559","BK4566"],"gpt_icon":0},{"id":"2539224003","title":"Femasys prices 3.6M shares at 85c in underwritten public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2539224003","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539224003?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:15","pubTimestamp":1748607351,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $0.85...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-prices-3-6m-shares-at-85c-in-underwritten-public-offering-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-prices-3-6m-shares-at-85c-in-underwritten-public-offering-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","FEMY","BK4584","BK4539"],"gpt_icon":0},{"id":"2539244802","title":"BRIEF-Femasys Announces Pricing Of Underwritten Public Offering And Concurrent Private Placement With Gross Proceeds Of $4.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2539244802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539244802?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:04","pubTimestamp":1748606699,"startTime":"0","endTime":"0","summary":"BRIEF-Femasys Announces Pricing Of Underwritten Public Offering And Concurrent Private Placement With Gross Proceeds Of $4.5 MillionMay 30 (Reuters) - Femasys Inc FEMY.O:FEMASYS ANNOUNCES PRICING OF U","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUAXVZRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","FEMY","BK4584","BK4082"],"gpt_icon":0},{"id":"2539224626","title":"Femasys Inc - Prices Public Offering of 3.6 Mln Shares at $0.85/Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2539224626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539224626?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:00","pubTimestamp":1748606401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUAXVZRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4539","BK4082","FEMY"],"gpt_icon":0},{"id":"2539222481","title":"Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement With Gross Proceeds of $4.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2539222481","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539222481?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:00","pubTimestamp":1748606401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUAXVZRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4584","FEMY","BK4539"],"gpt_icon":0},{"id":"2539241333","title":"Teva Pharmaceutical (TEVA) Receives a Buy from UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2539241333","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539241333?lang=en_us&edition=fundamental","pubTime":"2025-05-30 16:26","pubTimestamp":1748593582,"startTime":"0","endTime":"0","summary":"UBS analyst Ashwani Verma maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $24.00. The compa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/teva-pharmaceutical-teva-receives-a-buy-from-ubs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/teva-pharmaceutical-teva-receives-a-buy-from-ubs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4557","BK4584","TEVA","BK4585","BK4588","BK4559","BK4007","BK4566","BK4596"],"gpt_icon":0},{"id":"2539216384","title":"BUZZ-Australia's Lynas Rare Earths gains on signing rare earths deal with Malaysian co","url":"https://stock-news.laohu8.com/highlight/detail?id=2539216384","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539216384?lang=en_us&edition=fundamental","pubTime":"2025-05-30 10:33","pubTimestamp":1748572421,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Lynas Rare Earths gains on signing rare earths deal with Malaysian co** Shares of Australia's Lynas Rare Earths LYC.AX rise as much as 3.2% to A$8.030, their biggest intraday gain since May 22** Rare earths producer signs memorandum of understanding for supply of mixed rare earths carbonate from Malaysia's Menteri Besar  Inc** Agreement provides framework for MB Inc. and Lynas to negotiate a definitive agreement for supply MREC feedstock to the Lynas Malaysia advanced materials plant - LYC** Stock has risen nearly 21% this year, as of 0226 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nL3N3S2072:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7507","BK4584","DARE","LYC.AU","BK4007","BK7095"],"gpt_icon":0},{"id":"2539295982","title":"Femasys Inc. Announces Public Offering of Common Stock and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2539295982","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539295982?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:23","pubTimestamp":1748550206,"startTime":"0","endTime":"0","summary":"Femasys Inc., a leading biomedical innovator in women's health, announced its intention to offer and sell shares of its common stock in a public offering, with the option for underwriters to purchase an additional 15% of the shares. Concurrently, certain existing institutional stockholders and company directors and officers have shown interest in a private placement of shares. The offerings aim to fund the company's commercial expansion, product development, and general corporate purposes. JonesTrading Institutional Services LLC is managing the public offering and private placement. The public offering is registered under a statement filed with the U.S. Securities and Exchange Commission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDLxkmhv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4588","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2210149790.SGD","FEMY","LU2095319765.USD","NDAQ","BK4539","IE00BGHQF748.EUR","BK4082","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","BK4585"],"gpt_icon":0},{"id":"2539295924","title":"Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2539295924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539295924?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:23","pubTimestamp":1748550197,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA27LM8H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4584","BK4539","FEMY"],"gpt_icon":0},{"id":"2539250155","title":"Teva reaffirms ‘Pivot to Growth’ strategy with launch of acceleration phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2539250155","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539250155?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:15","pubTimestamp":1748520943,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical is hosting a 2025 Innovation & Strategy Day, to launch the acceleration phase of its “Pivot to Growth” strategy and to d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-reaffirms-pivot-to-growth-strategy-with-launch-of-acceleration-phase-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-reaffirms-pivot-to-growth-strategy-with-launch-of-acceleration-phase-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4585","BK4596","STRK","TEVA","BK4516","BK4559","BK4595","BK4600","BK4566","BK4023","BK4557","BK4588","BK4007"],"gpt_icon":0},{"id":"2539257430","title":"Teva Reaffirms “Pivot to Growth” Strategy Progress With Launch of Acceleration Phase at 2025 Innovation and Strategy Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2539257430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539257430?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:00","pubTimestamp":1748520003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA82WVGD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4559","BK4584","BK4588","BK4007","TEVA","BK4557","BK4596","BK4566","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}]}}